AVITA Medical Inc (ASX: AVH) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

AVITA Medical Inc Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $178.38 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 152.47 million
Earnings per share -0.362
Dividend per share N/A
Year To Date Return 2.86%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • AVITA Medical Inc (ASX: AVH)
    Latest News

    A group of science or medical professionals cheering good news in the lab.
    Share Gainers

    Avita Medical (ASX:AVH) share price jumps on FDA approval

    Avita shares have landed in the green from the market open. Here are the details...

    Read more »

    Investor with palm up and graphic illustration of asx small cap tech shares charts shooting from his hand
    Investing Strategies

    5 ASX shares to hold for 5 years

    Professional investors can't necessarily stick to a long-term 'buy and hold' strategy. But here are 5 stocks they would pick…

    Read more »

    asx share price on watch represented by group of prople all looking through magnifying glasses
    Small Cap Shares

    3 small cap ASX shares to watch

    Keep an eye on these small cap shares...

    Read more »

    hand with two fingers
    Ask a Fund Manager

    2 ASX shares to hold onto for the next 5 years

    Ask A Fund Manager: The Montgomery Fund's Joseph Kim names the stocks that he'd be delighted to keep for the…

    Read more »

    best and worse asx shares represented by green best button and red worst button
    Share Market News

    Best and worst performing ASX sectors of financial year 2021

    In the new fiscal year, will you bet on the industries that did well or have stumbled in the past…

    Read more »

    A healthcare worker wearing a white coat holds his fingers to his mouth looking worried as healthcare stocks like Cochlear crash today
    Healthcare Shares

    Hold your nerve on this battered ASX share: expert

    This healthcare stock has caused plenty of headaches for investors. But is it about to turn a corner?

    Read more »

    Woman cheering in front of laptop as she watches the Metal Hawk share price rise
    Small Cap Shares

    Why analysts rate these small cap ASX shares as buys

    Analysts rate these small cap ASX shares highly...

    Read more »

    bull market encapsulated by bull running up a rising stock market price
    Share Market News

    ASX 200 rises again, Avita jumps, Shaver Shop sinks

    The Avita share price was a top performer as the ASX 200 went up again.

    Read more »

    A businessman points to and arrow going up on a graph, indicating a share price rise for an ASX company
    Share Gainers

    Why AVITA, Cettire, Lifestyle Communities, & SEEK are storming higher

    These ASX shares are having a strong day...

    Read more »

    A happy person clenching fists in celebration sitting at computer.
    Share Gainers

    Why the AVITA (ASX:AVH) share price is jumping 8% today

    It has been a good day so far for this healthcare share...

    Read more »

    green arrow representing a rise in the share price
    Share Gainers

    Why Afterpay, Altium, AVITA, & Domino's shares are pushing higher

    These ASX shares are ending the week on a positive note...

    Read more »

    four excited doctors with their hands in the air
    Healthcare Shares

    Why the Avita Medical (ASX:AVH) share price is soaring 14%

    Investors have reacted favourably to some positive news from the medical technology business.

    Read more »

    Frequently Asked Questions

    No, AVITA Medical does not pay dividends at this time.

    AVITA Medical Inc listed on the ASX on 24 June 2020.

    Yes, as well as being listed on the ASX, AVITA Medical Inc is listed on the US Nasdaq where it trades under the ticker NASDAQ: RCEL.

    AVH ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About AVITA Medical Inc

    AVITA Medical Inc (ASX: AVH) is a healthcare company specialising in regenerative medicine. It is best known for its RECELL system, a burn treatment device that creates 'spray-on skin' from a patient's own skin cells within 30 minutes, avoiding or reducing the need for skin grafts.

    The product was originally invented and patented by Western Australian doctor and clinical professor Fiona Wood in 1993. 

    RECELL is approved for use in Australia, Europe, Canada, China, the Middle East, and Africa. It is also approved for treating adult patients in the US. As well as burns, AVITA Medical has evidence of RECELL's effectiveness for additional skin applications, such as treating chronic and traumatic wounds, scar revision, and vitiligo. 

    AVITA Medical Inc is domiciled and also listed on the US Nasdaq where it trades under the ticker NASDAQ: RCEL.

    AVH Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    20 Jan 2026 $1.17 $-0.03 -2.50% 455,293 $1.18 $1.20 $1.16
    19 Jan 2026 $1.20 $0.12 11.11% 1,214,004 $1.15 $1.21 $1.14
    16 Jan 2026 $1.08 $0.02 1.88% 427,045 $1.07 $1.11 $1.06
    15 Jan 2026 $1.07 $-0.04 -3.62% 782,753 $1.07 $1.08 $1.05
    14 Jan 2026 $1.11 $0.08 7.84% 898,919 $1.06 $1.13 $1.05
    13 Jan 2026 $1.02 $-0.03 -2.84% 334,574 $1.06 $1.06 $1.02
    12 Jan 2026 $1.06 $0.05 4.98% 560,041 $1.03 $1.09 $1.03
    09 Jan 2026 $1.01 $-0.04 -3.85% 681,993 $1.02 $1.03 $1.01
    08 Jan 2026 $1.04 $0.00 0.00% 535,148 $1.00 $1.05 $1.00
    07 Jan 2026 $1.05 $-0.02 -1.89% 287,685 $1.05 $1.08 $1.05
    06 Jan 2026 $1.06 $-0.05 -4.50% 367,839 $1.08 $1.09 $1.06
    05 Jan 2026 $1.11 $0.01 0.91% 308,745 $1.09 $1.12 $1.08
    02 Jan 2026 $1.10 $0.05 4.76% 400,753 $1.06 $1.12 $1.06
    31 Dec 2025 $1.05 $0.01 0.96% 255,932 $1.06 $1.10 $1.05
    30 Dec 2025 $1.05 $-0.02 -1.89% 109,413 $1.06 $1.07 $1.05
    29 Dec 2025 $1.06 $0.00 0.00% 111,071 $1.06 $1.07 $1.05
    24 Dec 2025 $1.06 $0.01 0.95% 172,811 $1.06 $1.07 $1.04
    23 Dec 2025 $1.06 $-0.02 -1.87% 326,883 $1.08 $1.08 $1.04

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    16 Oct 2025 James Corbett Exercise 2,891 $4,712
    Conversion of securities. As per announcement
    16 Oct 2025 James Corbett Buy 2,891 $4,712
    Conversion of securities. As per announcement
    29 Aug 2025 Robert McNamara Buy 10,000 $45,000
    On-market trade. USD $
    20 Aug 2025 Robert McNamara Buy 10,000 $50,000
    On-market trade. USD $, As per announcement on 27-08-2025
    06 Jun 2025 Robert McNamara Issued 9,200 $16,606
    Conversion of securities.
    06 Jun 2025 Robert McNamara Exercise 9,200 $16,606
    Conversion of securities. 16,938 RSUs
    06 Jun 2025 Cary Vance Issued 9,200 $16,606
    Conversion of securities.
    06 Jun 2025 Cary Vance Exercise 9,200 $16,606
    Conversion of securities. 16,938 RSUs
    06 Jun 2025 Louis (Lou) Panaccio Exercise 9,200 $16,606
    Conversion of securities. 10,022 RSUs
    06 Jun 2025 Louis (Lou) Panaccio Issued 9,200 $16,606
    Conversion of securities.
    06 Jun 2025 Suzanne Crowe Issued 9,200 $16,606
    Conversion of securities. 22,990 CDIs
    06 Jun 2025 Suzanne Crowe Exercise 9,200 $16,606
    Conversion of securities. 10,022 RSUs
    06 Jun 2025 Jeremy Curnock-Cook Issued 9,200 $16,606
    Conversion of securities.
    06 Jun 2025 Jeremy Curnock-Cook Exercise 9,200 $16,606
    Conversion of securities. 10,022 RSUs
    06 Jun 2025 Jan Reed Issued 9,200 $16,606
    Conversion of securities.
    06 Jun 2025 Jan Reed Exercise 9,200 $16,606
    Conversion of securities. 12,913 RSUs
    05 Jun 2025 James Corbett Issued 520,000 $951,600
    Issue of options.
    05 Jun 2025 Louis (Lou) Panaccio Issued 4,295 $7,859
    Issue of options.
    05 Jun 2025 Louis (Lou) Panaccio Issued 10,022 $18,340
    Issue of securities. 19,222 RSUs
    05 Jun 2025 Jan Reed Issued 4,295 $7,859
    Issue of options.
    05 Jun 2025 Jan Reed Issued 10,022 $18,340
    Issue of securities. 22,113 RSUs
    05 Jun 2025 Jeremy Curnock-Cook Issued 10,022 $18,340
    Issue of securities. 19,222 RSUs
    05 Jun 2025 Jeremy Curnock-Cook Issued 4,295 $7,859
    Issue of options.
    05 Jun 2025 Suzanne Crowe Issued 4,295 $7,859
    Issue of options.
    05 Jun 2025 Suzanne Crowe Issued 10,022 $18,340
    Issue of securities. 19,222 RSUs
    05 Jun 2025 Robert McNamara Issued 10,022 $18,340
    Issue of securities. 26,138 RSUs
    05 Jun 2025 Robert McNamara Issued 4,295 $7,859
    Issue of options.
    05 Jun 2025 Cary Vance Issued 10,022 $18,340
    Issue of securities. 26,138 RSUs
    05 Jun 2025 Cary Vance Issued 4,295 $7,859
    Issue of options.
    07 Mar 2025 Robert McNamara Buy 11,000 $91,300
    On-market trade. USD$
    21 Feb 2025 Robert McNamara Buy 10,000 $100,900
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Professor Suzanne Crowe Non-Executive Director Jan 2016
    Ms Crowe is a physician-scientist and ASX/Nasdaq-listed company director with expertise in supporting companies with their medical and scientific strategies. She is currently a Director of Sonic Healthcare Ltd, a large global medical diagnostics company. Past board positions include St. Vincent's Health Australia Ltd (2012-2021), the country's largest not-for-profit health and aged care provider. After 35 years at both, she has recently retired from the Burnet Institute, having served as Associate Director Clinical Research, and The Alfred Hospital Melbourne, where she held the appointment of Senior Specialist Physician in Infectious Diseases. She was appointed as Officer of the Order of Australia in June 2020 in recognition of her services to health, clinical governance, biomedical research, and education.
    Mr Jeremy Curnock-Cook Non-Executive Director Oct 2012
    Mr Cook is a veteran in the life sciences/healthcare industry and has been actively supporting the commercialization of healthcare innovations and helping entrepreneurs build their international businesses over the past 45 years. Founder and Managing Director of BioScience Managers, Mr. Curnock Cook brings his international experience to our Board of Directors. Over his career, Mr. Curnock Cook has successfully managed more than US $1 billion in equity investments. He launched the first dedicated biotechnology fund for the Australian market and is a former head of the life science private equity team at Rothschild Asset Management. In his early career he founded the International Biochemicals Group which he successfully sold to Royal Dutch Shell. Mr. Curnock Cook founded a European-focused seed fund with Johnson & Johnson and built the International Biotechnology Trust. Mr. Curnock Cook has served on more than 40 boards of directors in the life science sector in the UK, Europe, USA, Canada, Japan and Australia.
    Ms Jan Stern Reed Non-Executive Director Jul 2021
    Ms Reed has more than 35 years of legal, management and business leadership experience primarily within the healthcare industry, and brings expertise in corporate governance, compliance, and risk management. Ms. Reed served as Senior Vice President, General Counsel and Corporate Secretary at Walgreens Boots Alliance, Inc., a global health and wellbeing company. Prior to Walgreens, Ms. Reed was Executive Vice President, Human Resources, General Counsel and Corporate Secretary of Solo Cup Company, where she was responsible for the legal, human resources, internal audit, corporate communications, and compliance functions.
    Mr Cary Vance Non-Executive DirectorNon-Executive ChairmanInterim CEO Apr 2023
    Mr Vance brings over 25 years of executive leadership experience across the global healthcare industry, with a in transformative medical technologies. He previously held CEO roles at PhotoniCare, Inc., Titan Medical, XCath, OptiScan Biomedical, Myoscience, and Hansen Medical. Earlier in his career, he held senior leadership positions at Teleflex, Covidien, and GE HealthCare. Mr Vance is Lean/Six Sigma Black Belt Certified.
    Mr Robert McNamara Non-Executive Director Apr 2023
    Mr McNamara is a senior executive with over 25 years of leadership experience in public and privately held companies in the medical device and technology industries. His experience in operations and financial management spans across early stage, high growth, and mature companies. He is a former member of the Board of Directors and Chair of Audit Committee for Axonics, Inc. Additionally, Mr. McNamara is a member of the Board of Directors, Chair of the Compensation Committee, and member of the Audit Committee for Xtant Medical Holdings. Prior to these appointments, Mr. McNamara served as Executive Vice President, Chief Financial Officer of LDR Holding/Spine. Prior to this role, he served as the Chief Financial Officer of three publicly traded medical device companies including Accuray, Somnus Medical Technologies, and Target Therapeutics.
    Dr Michael Eric Tarnoff Non-Executive Director Aug 2025
    Mr Tarnoff, spent 23 years at Tufts Medical Center in various executive roles, recently as Chief Physician Executive and CEO until 2024. He also served as Chief Medical Officer and Vice President, Medical Affairs at Medtronic from 2015 to 2019. From 2008 to 2015, he was corporate Chief Medical Officer and Vice President at Covidiens Surgical Devices division. His earlier roles include Medical Director at GI Dynamics (2006-2008) and Chief Medical Consultant at Tyco Healthcare (2005-2008).
    Mr Joseph(Joe) Fralin Woody Non-Executive Director Jan 2026
    Mr Woody is a healthcare executive with more than two decades of leadership experience across the medical technology sector, recently serving as CEO of Avanos Medical from 2017 to 2024, and previously, as President and CEO of Acelity Holdings. His background spans multiple senior executive roles, including with Covidien and Smith & Nephew. Across his storied professional career, Mr Woody also served on the Board of Directors of AdvaMed, Inc., the trade association in the U.S. for the medical device, diagnostics, and digital health technology sectors, for over a decade
    Mr Mark Andrew Licciardo Company Secretary Mar 2018
    -
    Ms Nicole Linda Kelsey Chief Legal and Compliance OfficerCompany Secretary Jul 2024
    -
    David O'Toole Chief Financial Officer
    -
    Nicole Linda Kelsey Chief Legal and Compliance OfficerCompany Secretary
    -
    Mark Andrew Licciardo Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Washington H Soul Pattinson And Company Limited 392,529 1.49%
    Citicorp Nominees Pty Limited 391,741 1.49%
    BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> 388,055 1.47%
    UBS Nominees Pty Ltd 345,782 1.31%
    Abn Amro Clearing Sydney Nominees Pty Ltd <Custodian A/C> 177,865 0.67%
    Mr Evan Philip Clucas & Ms Leanne Jane Weston <Kuranga Nursery Super A/C> 177,013 0.67%
    JP Morgan Nominees Australia Pty Limited 113,074 0.43%
    HSBC Custody Nominees (Australia) Limited 112,967 0.43%
    Taggart Investments Pty Ltd <Taggart Investment A/C> 86,000 0.33%
    BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> 76,729 0.29%
    Ioof Investment Services Limited <Ips Superfund A/C> 71,116 0.27%
    Neweconomy Com Au Nominees Pty Limited <900 Account> 70,808 0.27%
    BNP Paribas Nominees Pty Ltd <Clearstream> 70,704 0.27%
    HSBC Custody Nominees (Australia) Limited i 65,237 0.25%
    HSBC Custody Nominees (Australia) Limited <Gsco Customers A/C> 61,465 0.23%
    Mr Andre Wall Ellis & Mrs Olivia Louise Ellis 60,000 0.23%
    Mrs Arlene Perry 60,000 0.23%
    Wairahi Investments Limited 60,000 0.23%
    Mr David Anthony Deelen 57,200 0.22%
    Dental Union Of Australia Pty Ltd <Ian Weatherlake S/F A/C> 56,000 0.21%

    Profile

    since

    Note